Oxford BioMedica (OTCMKTS:OXBDF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. “
OXBDF stock opened at $9.07 on Wednesday. Oxford BioMedica has a 1-year low of $5.00 and a 1-year high of $22.50.
Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.
Featured Story: Book Value Of Equity Per Share – BVPS Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.